136 results about "Bicyclo Compounds" patented technology

A liquid crystal composition is provided that satisfies at least one characteristic among the characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a large optical anisotropy, a large dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light and a high stability to heat, or is properly balanced regarding at least two characteristics. An AM device is provided that has a short response time, a large voltage holding ratio, a large contrast ratio, a long service life and so forth. The liquid crystal composition contains a specific tricyclic compound having a large optical anisotropy as the first component and a specific tetracyclic compound having a large dielectric anisotropy as the second component, and may contain a specific bicyclic compound having a particularly small viscosity as the third component. The liquid crystal composition has a nematic phase. The liquid crystal display device contains the liquid crystal composition.

CRF antagonists comprising as an active ingredient, the compound of formula (I)

wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W¹ and W² is carbon atom or nitrogen atom; Z is NR³, oxygen atom, sulfur which may be oxidized or CR⁴R⁵; R¹ is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)_nR⁶, COR⁷, or cyclic group which may be substituted; R² is unsaturated cyclic group which may be substituted.

New bicyclic compounds, their preparation, and their use as antibacterial agents, either alone or in combination with an antibiotic for the treatment of infections caused by β-lactamase-producing pathogenic bacteria, are described.

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

The subject is to provide a liquid crystal composition that satisfies at least one of characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a suitable optical anisotropy, a negatively large dielectric anisotropy, a large specific resistance and a high stability to ultraviolet light or heat, or that is suitably balanced regarding at least two of the characteristics. The subject is to provide a AM device that has a short response time, a large voltage holding ratio, a large contrast ratio, a long service life and so forth. The invention provides a liquid crystal composition that has negative dielectric anisotropy, including a specific four-ring compound having a high maximum temperature and a negatively large dielectric anisotropy as a first component, a two-ring compound having a small viscosity as a second component, and optionally including a specific compound having a negatively large dielectric anisotropy as a third component, a specific compound having small viscosity as a fourth component and a specific compound having a negatively large dielectric anisotropy as a fifth component. The invention provides also a liquid crystal display device containing this composition.

Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula

A representative example is:

A novel compound represented by the following formula (1) or a salt thereof:

wherein symbol “A” represents a saturated heterocyclic group, a 5-membered heteroaromatic group having two heteroatoms in the ring, a group represented by the formula A1 (R², R³, and R⁴ represent hydrogen atom, hydroxyl group, etc.), etc., B represents a group represented by the formula B1 (R¹¹ represents hydrogen atom, hydroxyl group, etc.), etc., R¹ represents an alkyl group, and symbol “n” represents an integer of 2 to 6, which has a parathyroid hormone depressing action and showing low toxicity, and a medicament containing the compound or salt thereof as an active ingredient.

A liquid crystal composition has a negative dielectric anisotropy, and contains a specific bicyclic compound having a large optical anisotropy and a small viscosity as a first component and a specific compound having a large maximum temperature and a large dielectric anisotropy as a second component, and may contain a specific compound having a small viscosity as a third component, a specific compound having a large dielectric anisotropy as a fourth component and a specific compound having a large dielectric anisotropy as a fifth component, and a liquid crystal display device includes the composition.

A liquid crystal composition and an AM liquid crystal display device are described. The liquid crystal composition has a negative dielectric anisotropy, contains a specific compound having a large negative dielectric anisotropy as a first component and a two-ring compound having a small viscosity as a second component, and may further contain a specific compound having a large negative dielectric anisotropy as a third component, a specific compound having a small viscosity as a fourth component and a specific compound having a large negative dielectric anisotropy as a fifth component. The AM liquid crystal display device includes the liquid crystal composition.

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia,

wherein R₁, R₂, R₅, X, Y and n are defined herein.

The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia,

wherein R₁, R₂, R₅, X and n are defined herein.